Purple Biotech

Purple Biotech (NASDAQ/TASE: PPBT) is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion & drug resistance

[Purple Biotech @_PurpleBiotech]

$PPBT Purple Biotech Announces AI Collaboration with Converge Bio to Accelerate Development of its Next-Generation Tri-Specific Antibody Platform

Read the full press release here: https://t.co/BfHfc5VBTQ

[Purple Biotech @_PurpleBiotech]

$PPBT Purple Biotech Regains Compliance with Nasdaq Minimum Bid Price Requirement

Read the full press release here:
https://t.co/cWnn1oGSpj

[Purple Biotech @_PurpleBiotech]

$PPBT Purple Biotech Announces CEO Transition

Read the full press release here: https://t.co/rggQ2Q6L6A

[Purple Biotech @_PurpleBiotech]

$PPBT Purple Biotech Reports Fourth Quarter and Full Year 2025 Financial Results

Read the full press release here: https://t.co/dyC0g825AM

[Purple Biotech @_PurpleBiotech]

$PPBT Purple Biotech Announces Plan to Implement ADS Ratio Change

Read the full press release here: https://t.co/v719DYE1JO

[Purple Biotech @_PurpleBiotech]

$PPBT Purple Biotech Achieves Toxicology Milestone Demonstrating an Expanded Therapeutic Window for CAPTN-3 Platform Tri-specific Antibody, IM1240

Read the full press release here: https://t.co/lc9CK8kEsY

[Purple Biotech @_PurpleBiotech]

$PPBT Purple Biotech Reports Positive New Preclinical Data Demonstrating Multi-Arm Anti-Tumor Activity Across Two CAPTN-3 Tri-Specific Antibodies at ESMO Immuno-Oncology Congress 2025

Read the full press release here: https://t.co/19xuWmOrLi

[Purple Biotech @_PurpleBiotech]

$PPBT Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress

Read the full press release here: https://t.co/KKE1UvgKat

[Purple Biotech @_PurpleBiotech]

We are thrilled to announce the initiation of the Phase 2 study for CM24 as a potential 2L treatment for patients with #PDAC, expanding the potential for treatment for #patients while extending our cash runway through 2024. More: https://t.co/Fq7PEDxoRy #oncology #cancer #PDAC

[Purple Biotech @_PurpleBiotech]

We are pleased to share interim safety & efficacy in our Phase 1b Study of CM24 in Combination w/ Opdivo at #AACR22 saw 1 confirmed PR & 3 SD in patients with advanced pancreatic cancer and PTC. 9 patients still in study follow-up

#oncology #Cancer

https://t.co/eVL7qvJzf2

[Purple Biotech @_PurpleBiotech]

We are pleased to issue the following letter from its Chief Executive Officer, Isaac Israel, to its shareholders: https://t.co/U1nW1k3gHp

#cancerresearch #curecancer #oncology

[Purple Biotech @_PurpleBiotech]

4/4 We look forward to present an overview of our ongoing Phase 1b/2 clinical trial of CM24 at @myESMO #oncology #ESMO21

[Purple Biotech @_PurpleBiotech]

1/4 We are excited to provide an update about our ongoing Phase 1b/2 clinical trial of CM24 for the treatment of multiple advanced cancers #oncology #CancerResearch #PancreaticCancer https://t.co/i4yuCFAhvy

[Purple Biotech @_PurpleBiotech]

3/4 After only two treatment cycles, one patient saw a partial response of 40%, with a definite reduction of the paratracheal adenopathy and liver lesions and a 56% reduction in CA19-9 tumor marker

[Purple Biotech @_PurpleBiotech]

Purple is excited to announce that NT219 was well-tolerated in initial clinical data from our ongoing Phase 1/2 study with a partial response observed in a patient with refractory GE junction cancer #CancerResearch #ASCO21 #Curecancer https://t.co/29wnQWu7Um

[Purple Biotech @_PurpleBiotech]

Purple Biotech to present interim data from our ongoing Phase 1/2 clinical trial of NT219, a monotherapy for the treatment of solid tumors that has the potential to help people living with hard-to-treat cancers, on June 4 #ASCO21 #cancer #cancerresearch #oncologyresearch

[Purple Biotech @_PurpleBiotech]

Happy to present new data supporting NT219's MOA, a dual inhibitor, novel SM targeting IRS1/2 & STAT3 at the Epigenetics and Metabolism AACR Virtual Conference by researchers at TASMC & Tel-Aviv University #cancer #tasmc
https://t.co/KRhj1AKYVf

[Purple Biotech @_PurpleBiotech]

Proud to present the anti-tumor activity of NT219 in pembrolizumab-resistant head and neck cancer PDX models at AACR 2020 virtual meeting II #Cancer #AACR2020 #keytdura #oncology #headandneckcancer